Targeting mitoNEET to reduce brain damage after a stroke
Official title: mitoNEET as a therapeutic target for mitigating ischemic brain injury following MCAO
Funded at West Virginia University · NIH-10912765 · Data updated 2026-11-12
This study is looking at how a special protein called mitoNEET can help protect brain cells during a stroke, and it aims to test a new treatment that might improve recovery and reduce damage to the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project start | September 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $526,872 |
| NIH project number | 5R01NS129998-02 |
| Project ID | NIH-10912765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced an ischemic stroke and are in the acute phase of recovery.
✕Less likely to help
Patients who have not suffered a stroke or have chronic neurological conditions unrelated to ischemic brain injury may not benefit from this research.
What this research studies
This research investigates how targeting a specific protein called mitoNEET can help protect brain cells from damage caused by ischemic strokes. The study focuses on understanding the role of mitochondria in brain injury and aims to develop a new treatment using a compound called NL-1, which has shown promise in improving brain function in animal models. By exploring how mitoNEET functions in the brain, the researchers hope to find ways to enhance recovery and reduce cell death following a stroke.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery outcomes for stroke patients.
How similar studies have gone: Previous research has shown that targeting mitochondrial dysfunction can lead to improvements in stroke recovery, suggesting that this approach has potential for success.
Where this research is happening
-
West Virginia University
Morgantown, United States Active
Researchers
- Principal investigator: Huber, Jason D — West Virginia University
- Study coordinator: Huber, Jason D
Related research
Other NIH-funded projects on the same topics.
-
Waixenicin A-based therapy for newborn brain injury
A new drug-target approach aims to protect babies’ brains after oxygen deprivation at birth.
-
AI-enhanced virtual reality tool to support remote emergency brain surgery training in Tanzania
A new AI-powered virtual reality tool helps non-experts in low-resource areas get real-time remote guidance for emergency traumatic brain injury surgery.
-
Modulating a brain lipid to reduce injury after newborn brain injury
Aims to test a treatment that changes a brain lipid to lessen damage after a baby’s brain has been deprived of oxygen.
-
How head injury affects the heart and blood vessels
This project aims to find out whether traumatic brain injuries make people more likely to develop hardened arteries and heart problems, especially among veterans.
-
Brain injury risk in preterm babies with heart disease and how surgery choices affect their brains
This project follows newborns with congenital heart disease born early to understand how their brains are affected and how different surgical approaches might influence outcomes.
-
Neural targets for improving function in Veterans with alcohol use disorder and mild brain injury
This project tests a targeted brain-stimulation approach to help Veterans who have both alcohol use problems and mild traumatic brain injury improve daily functioning.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.